COMPASS Pathways plc – NASDAQ:CMPS
Founder-led company
COMPASS Pathways stock price today
$4.12
+0.12
+3.26%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
COMPASS Pathways stock price monthly change
-42.76%
month
COMPASS Pathways stock price quarterly change
-42.76%
quarter
COMPASS Pathways stock price yearly change
-55.91%
year
COMPASS Pathways key metrics
Market Cap | 269.57M |
Enterprise value | 297.51M |
P/E | -4.74 |
EV/Sales | N/A |
EV/EBITDA | -3.27 |
Price/Sales | N/A |
Price/Book | 2.42 |
PEG ratio | 0.22 |
EPS | -2.37 |
Revenue | N/A |
EBITDA | -140.38M |
Income | -129.72M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCOMPASS Pathways stock price history
COMPASS Pathways stock forecast
COMPASS Pathways financial statements
| Jun 2023 | 0 | -28.33M | |
|---|---|---|---|
| Sep 2023 | 0 | -33.38M | |
| Dec 2023 | 3.68M | -32.81M | -891.05% |
| Mar 2024 | 0 | -35.18M |
| Dec 2023 | 3.68M | -32.81M | -891.05% |
|---|---|---|---|
| Mar 2024 | 0 | -35.18M | |
| Oct 2025 | 0 | -29.86M | |
| Dec 2025 | 0 | -29.54M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 209834000 | 43.43M | 20.7% |
|---|---|---|---|
| Sep 2023 | 299033000 | 45.77M | 15.31% |
| Dec 2023 | 275987000 | 50.24M | 18.2% |
| Mar 2024 | 308993000 | 49.83M | 16.13% |
| Jun 2023 | -24.81M | -17K | 55.92M |
|---|---|---|---|
| Sep 2023 | -17.05M | -18K | 116.78M |
| Dec 2023 | -27.85M | 34 | -52.71K |
| Mar 2024 | -20.81M | 0 | 63.47M |
COMPASS Pathways alternative data
| Aug 2023 | 181 |
|---|---|
| Sep 2023 | 181 |
| Oct 2023 | 181 |
| Nov 2023 | 181 |
| Dec 2023 | 181 |
| Jan 2024 | 181 |
| Feb 2024 | 181 |
| Mar 2024 | 186 |
| Apr 2024 | 186 |
| May 2024 | 186 |
| Jun 2024 | 186 |
| Jul 2024 | 186 |
COMPASS Pathways other data
14.03%
-3.84%
of CMPS is owned by hedge funds
63
-41
5.95M
-1.64M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 16928 |
| Jan 2024 | 0 | 373854 |
| May 2024 | 0 | 62414 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. George Jay Goldsmith (1954) Co-Founder, Chairman & Chief Executive Officer | $722,790 |
Dr. Ekaterina Malievskaia M.D. (1967) Co-Founder, Chief Innovation Officer & Executive Director | $536,400 |
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value
COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down
COMPASS Pathways And The Trillion Dollar Opportunity
The Growth Potential Of Psychedelics Stocks And ETFs
Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Will Tech Stocks Recover? 3 Names To Buy
-
What's the price of COMPASS Pathways stock today?
One share of COMPASS Pathways stock can currently be purchased for approximately $4.12.
-
When is COMPASS Pathways's next earnings date?
Unfortunately, COMPASS Pathways's (CMPS) next earnings date is currently unknown.
-
Does COMPASS Pathways pay dividends?
No, COMPASS Pathways does not pay dividends.
-
How much money does COMPASS Pathways make?
COMPASS Pathways has a market capitalization of 269.57M.
-
What is COMPASS Pathways's stock symbol?
COMPASS Pathways plc is traded on the NASDAQ under the ticker symbol "CMPS".
-
What is COMPASS Pathways's primary industry?
Company operates in the Healthcare sector and Medical - Care Facilities industry.
-
How do i buy shares of COMPASS Pathways?
Shares of COMPASS Pathways can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are COMPASS Pathways's key executives?
COMPASS Pathways's management team includes the following people:
- Mr. George Jay Goldsmith Co-Founder, Chairman & Chief Executive Officer(age: 71, pay: $722,790)
- Dr. Ekaterina Malievskaia M.D. Co-Founder, Chief Innovation Officer & Executive Director(age: 58, pay: $536,400)
-
Is COMPASS Pathways founder-led company?
Yes, COMPASS Pathways is a company led by its founders Mr. George Jay Goldsmith and Dr. Ekaterina Malievskaia M.D..
-
How many employees does COMPASS Pathways have?
As Jul 2024, COMPASS Pathways employs 186 workers.
-
When COMPASS Pathways went public?
COMPASS Pathways plc is publicly traded company for more then 4 years since IPO on 18 Sep 2020.
-
What is COMPASS Pathways's official website?
The official website for COMPASS Pathways is compasspathways.com.
-
How can i contact COMPASS Pathways?
COMPASS Pathways can be reached via phone at +44 6469053974.
COMPASS Pathways company profile:
COMPASS Pathways plc
compasspathways.comExchange:
NASDAQ
Full time employees:
186
Industry:
Medical - Care Facilities
Sector:
Healthcare
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
33 Broadwick Street
London, W1F 0DQ
London, W1F 0DQ
CIK: 0001816590
ISIN: US20451W1018
CUSIP: 20451W101
